Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults with Autoimmune Disease

Next Previous
Trial Profile

A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults with Autoimmune Disease

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADI-001 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Lupus nephritis; Myositis; Stiff-person syndrome; Systemic lupus erythematosus; Systemic scleroderma
  • Focus Adverse reactions
  • Sponsors Adicet Bio

Most Recent Events

  • 06 May 2025 According to Adicet media release, this trial is now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE)
  • 06 May 2025 According to Adicet media release, the Company expects to initiate enrollment for patients with systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) in the Phase 1 trial in 3Q/2025.
  • 06 May 2025 According to Adicet media release, the company expect to report preliminary Phase 1 data in the second half of 2025, subject to study site initiation and patient enrollment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top